

Special Issue

Treg Cell Immunotherapy in Cancer

Message from the Guest Editor

Depleting Treg cells from the tumor microenvironment has the potential to immensely improve antitumor immune responses, but Treg targeting approaches are being challenged by 2 main issues: (i) Treg cells share many markers with conventional T cells and therefore cannot be utilized as targets to specifically eradicate Treg cells without interfering with effector functions, (ii) universal Treg cell depletion can be complicated with severe autoimmunity. This issue of *Cancers* is dedicated to this topic, aiming to contribute to better understanding of the aspects of Treg biology which shape antitumor immune responses and the potential of developing successful Treg targeting therapeutic interventions to improve cancer immunotherapy. We aim to cover all associated areas, including but not limited to the mechanisms of Treg cell migration, adaptation and survival in the tumor microenvironment, mechanisms of Treg mediated suppression of antitumor immune responses, and mainly novel therapeutic approaches to target Treg cells specifically in the tumor without causing autoimmune phenomena or interfering with effector functions.

Guest Editor

Dr. Maria Velegriaki

Pelotonia Institute for Immuno-Oncology, The Ohio State University
Comprehensive Cancer Center, Columbus, OH 43210, USA

Deadline for manuscript submissions

30 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/167403

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)